Immutep Limited PBMD
Set alert
No live quote for PBMD yet.
- Open
- 1.72
- Prev close
- 1.71
- Mkt cap
- 46.70M
- Vol
- 37.11K
- Avg vol
- 132.55K
- EPS
- -0.30
- P/E
- -5.70
- Div yield
- 0.00%
More statistics
- Low
- 1.70
- High
- 1.77
- Forward P/E
- -6.33
- Beta
- 1.39
- Short ratio
- 1.25
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.72
- 200-d avg
- 1.89
- 1y target
- 6.99
Key statistics
- Market cap
- 46.70M
- Enterprise value
- 32.09M
- Trailing P/E
- -5.70
- Forward P/E
- -6.33
- PEG ratio
- 0.00
- Price / sales
- 14.84
- Price / book
- 1.71
- EPS (TTM)
- -0.30
- Beta
- 1.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -227.54%
- Revenue (TTM)
- 3.15M
- Revenue growth
- 323.80%
- Free cash flow
- -3.89M
- Total cash
- 9.35M
- Total debt
- 4.42M
- Return on equity
- -30.29%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 1.72
- 200-day average
- 1.89
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 2016 | Maxim Group | init | — | Buy |
| Dec 29, 2015 | Roth Capital | init | — | Buy |
| Dec 2, 2015 | FBR Capital | init | — | Outperform |
| Oct 13, 2015 | H.C. Wainwright | init | — | Buy |
About Immutep Limited
Prima BioMed Ltd engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its core technologies are based on the lymphocyte activation gene-3 (LAG-3) immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The companys lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemoimmunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody for immunosuppression in autoimmune diseases; IMP701, a LAG-3 antagonist antibody for immunostimulation to treat cancer; and IMP761, a LAG-3 agonist antibody for immunosuppression in autoimmune diseases. The company is also developing CVac, an autologous dendritic cell therapy, which has completed Phase IIb clinical trials for ovarian cancer. Prima BioMed Ltd is headquartered in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- primabiomed.com.au
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PBMD — it syncs with the Stock Master app.